Posted by Michael Wonder on 20 Jun 2022
EMA publishes agenda for 20-23 June 2022 CHMP meeting
20 June 2022 - The EMA has published a draft agenda for this week's CHMP meeting.
The CHMP is due to issue opinions for the following technologies:
- Doxorubicin hydrochloride
- SARS-COV-2 virus (beta propiolactone inactivated)
- Ranibizumab
- Lasmiditan
- Valoctocogene roxaparvovec
- Asciminib hydrochloride
- Bevacizumab
- Efgartigimod alfa
